Intraarticular injection of microfragmented adipose tissue plus arthroscopy in isolated primary patellofemoral osteoarthritis is clinically effective and not affected by age, BMI, or stage of osteoarthritis

Michele Vasso¹, Katia Corona²*, Luigi Capasso¹, Giuseppe Toro¹ and Alfredo Schiavone Panni¹

Abstract

Purpose: This study aimed to report the clinical and functional results of a series of patients with isolated primary patellofemoral osteoarthritis (PFOA) treated with intraarticular injection of microfragmented autologous adipose tissue plus knee arthroscopy. The results were also analyzed in relation to the age and body mass index (BMI) of patients, and to the stage of PFOA.

Methods: Twenty-three patients with early-to-moderate (stage 1–3 according to the Iwano classification system) PFOA who received this treatment were retrospectively analyzed, with a mean follow-up of 22.1 ± 4.2 months. Patients were assessed using the International Knee Society (IKS) knee and function and visual analog scale (VAS) scores, and relative to their capacity for climbing stairs. Differences in improvements of IKS and VAS scores in relation to age (< 60 versus ≥ 60 years), BMI (< 30 versus ≥ 30 kg/m²), and stage of PFOA (stages 1–2 versus stage 3) were finally analyzed.

Results: The mean IKS knee score significantly improved from 35.6 ± 14.9 points preoperatively to 61.9 ± 17.8 points at the latest follow-up, while the mean IKS function score significantly improved from 52.0 ± 14.7 points preoperatively to 82.3 ± 19.1 points at the latest follow-up. The mean VAS score significantly decreased from 8.7 ± 2.2 preoperatively to 5.2 ± 2.5 at the latest follow-up. A significant improvement in the capacity to climb stairs was found. No significant differences in improvements of IKS knee and function and VAS scores were found in relation to age, BMI, or stage of PFOA.

Conclusion: Intraarticular injection of microfragmented autologous adipose tissue following arthroscopic debridement significantly improved overall clinical and functional scores in patients with early or moderate isolated primary PFOA at a mean follow-up of almost 2 years. Improvements were not significantly affected by age, BMI, or stage of PFOA.

Level of evidence: Level IV, retrospective case series.

Keywords: Adipose tissue, Adipose-derived stem cells, Patellofemoral osteoarthritis, Arthroscopic debridement, Knee

Introduction

Patellofemoral osteoarthritis (PFOA) is involved in more than 45% of knee osteoarthritis (OA) cases, either isolated (half of those cases) or associated with femorotibial...
degeneration [24]. Most patients with isolated PFOA present primary or idiopathic PFOA, while a minority of patients present PFOA secondary to patellar instability or trauma [10, 37]. Females aged ≥ 50 years appear to have a higher prevalence of PFOA (41%) compared with males aged ≥ 50 years (23%) [25]. The management of isolated primary PFOA is still highly controversial, especially in patients with early or moderate patellofemoral degeneration. In these patients, results of conservative treatment [physiotherapy and/or taping, intraarticular injections with hyaluronic acid and/or platelet-rich plasma (PRP)] or nonreplacement surgery (arthroscopy, chondroplasty, lateral facetectomy) are often ineffective, while replacement surgery is certainly premature [37].

Intraarticular cell therapies with mesenchymal stem cells (MSCs) have been widely used in the past few years for managing knee OA [4, 12, 31]. MSCs are multipotent stromal cells with the possibility to differentiate into chondrocytes with adequate stimuli (growth factors and cytokines), therefore adapting to the microenvironment where they reside [29]. More recently, adipose tissue has become an important source of MSCs due to its abundance, ease of access, and simplicity of harvesting. Adipose tissue contains a greater concentration of MSCs (up to 2%) than bone marrow (0.02%) [16, 31]. Additionally, adipose-derived stem cells (ASCs) present a higher proliferation and chondrogenic potential than other human MSCs, and this potential is less affected by the age of the patient-donors [5, 7, 20]. It has been reported how intraarticular injection of autologous adipose tissue rich in ASCs in patients with knee OA increased glycosaminoglycan and type II collagen content in hyaline cartilage [16, 27], and resulted in radiological evidence of improved cartilage volume and confirmed hyaline-like cartilage on histology [22]. These findings were in line with observed improved VAS scores and clinical outcomes. Although several studies have already shown promising results in patients with knee OA treated with intraarticular injection of adipose tissue rich in ASCs (both previously expanded or microfragmented in the operating room) associated or not to arthroscopic debridement [1, 11, 15, 16, 21, 22, 26, 34], the use of this treatment is not yet supported by strong scientific evidence [17], especially regarding PFOA. To our knowledge, no previous studies have evaluated the effectiveness of adipose tissue knee injection in patients with isolated primary PFOA.

The aim of this study was, therefore, to report the clinical and functional results of a series of patients with isolated primary PFOA treated with intraarticular injection of autologous adipose tissue rich in ASCs obtained through a commercially available technique that intraoperatively provided microfragmented and minimally manipulated adipose tissue without cell expansion or enzymatic treatment. At the same time, all the patients underwent knee arthroscopy. Additionally, overall clinical and functional results were analyzed in relation to the age and BMI of patients, as well as the stage of PFOA.

Materials and methods
From 2016 to 2020, 117 patients with generic knee OA underwent intraarticular injection of autologous microfragmented adipose tissue following knee arthroscopy. All operations were performed by two surgeons (M.V. and A.S.P.). The diagnosis of knee OA was made following the American College of Rheumatology criteria [30]. Selection criteria to perform this procedure were onset of symptoms of the index knee 6 or more months ago, and/or failure of the conservative treatment. Contraindications and exclusion criteria were recent trauma of the symptomatic knee with evident acute involvement of ligaments and/or menisci, infectious joint disease, chondromatosis or villonodular synovitis of the knee, malignancy, pregnancy, and patients on anticoagulant therapy or suffering from thrombocytopenia and/or coagulation disorder. Age and BMI were not considered a factor influencing the decision to use this protocol, although patients older than 80 years were generally excluded.

The surgical procedure has been described previously [35]. Saline solution (250 ml) was mixed with two doses of 7% ropivacaine and half a dose of adrenaline, and 150–180 ml was percutaneously injected in the abdominal subcutaneous adipose tissue (Fig. 1). Before surgery (at least 10 min later) adipose tissue aspiration, knee arthroscopy was performed to manage any intraarticular lesions. A standard liposuction technique was then performed (Fig. 2), and the harvested fat (40–60 ml) was introduced into the Lipogems ortho kit (LIPOGEMS International SpA, Milan, Italy) (Fig. 3), according to the manufacturer’s instructions, as previously described [3]. The processed final microfragmented adipose tissue product was transferred to 10 ml syringes (Fig. 4) and injected (10–15 ml) intraarticularly after closing the knee arthroscopy portals with a 3.0 non-resorbable suture (Fig. 5).

Of the 117 patients who received this protocol, 23 patients with isolated primary PFOA were retrospectively selected and finally included in the study; the remaining 94 patients with femorotibial OA (isolated or associated to PFOA) and/or with PFOA secondary to previous patellofemoral instability or trauma were excluded. In particular, to be retrospectively included into the study, the 23 selected patients had to meet the following criteria: radiographic and (successive) arthroscopic findings of isolated primary PFOA, clinical history of prevalent anterior knee pain exacerbated by stair climbing, and absence of previous patellofemoral instability or trauma.
The 23 patients finally included into the study received only chondral shaving/abrasion and/or meniscal regularization (debridement) through the arthroscopic procedure. The postoperative regimen was the same for all 23 patients. Immediate full weight-bearing was allowed according to the feeling of each patient. Immediate knee mobilization and muscular strength exercises were started from the first postoperative day and continued for at least 3 weeks. Seven days postoperatively, all the patients were medicated and desutured. The preoperative demographic data of these patients are listed in Table 1. All those patients presented early-to-moderate (stage 1–3 according to the Iwano classification system [19]) PFOA, while none of the patients presented stage 4 (bone-on-bone) PFOA. The mean follow-up was 22.1 ± 4.2 (range, 15–30) months. Patients had been assessed preoperatively and postoperatively through the International Knee Society (IKS) knee and function scores [18] and VAS pain score. Relative to the ability to climb stairs, patients were subdivided into five groups: A: normal up and down; B: normal up, down with rail; C: up and down with rail; D: up with rail, unable down; E: unable. After surgery, patients were clinically evaluated after 3, 6, and 12 months, and every 36 months thereafter, according to personal symptomatology. Before surgery, all the patients were assessed using a detailed clinical history and an accurate physical examination; at same time, a complete radiographic study, including weight-bearing long-leg AP view radiographs, as well as Rosenberg, Merchant, and lateral projections, and magnetic resonance imaging (MRI) were performed. In general, radiographs and MRI studies were performed to diagnose and stage the OA (tibiofemoral and/or patellofemoral), and to evaluate any intraarticular lesion (ligaments, menisci, cartilage) before surgery. The ethics committee of the University of Naples (Italy) did not require approval for the review of patient records or images.

Statistical analyses were performed using SPSS (Statistical Package for Social Sciences) version 24.0 (IBM-SPSS,
New York, USA). Data were tested for normal distribution by the Kolmogorov–Smirnov Z test. Continuous variables were expressed using mean values ± standard deviation (SD) and range, and categorical variables were expressed as frequencies (percentages). For preoperative and postoperative comparisons of dependent variables, the paired Student’s t-test was used for normally distributed data. For differences in the objective stair climbing capacity, Pearson’s Chi-square test was used. Additionally, the patients were categorized into two subgroups in relation to age, BMI, and stage of PFOA, with a cutoff of 60 years of age, 30 kg/m², and stage 3 Iwano classification, respectively. Differences in improvements of IKS (knee and function) and VAS scores in relation to age, BMI, and stage of PFOA were tested by unpaired Student’s t-tests. The level of significance was set at $p < 0.05$.

**Results**

The mean IKS knee score improved from $35.6 \pm 14.9$ (range, 14–79) points preoperatively to $61.9 \pm 17.8$ (range, 27–92) points at the latest follow-up ($p < 0.001$), while the mean IKS function score improved from $52.0 \pm 14.7$ (range, 25–70) points preoperatively to $82.3 \pm 19.1$ (range, 35–100) points at the latest follow-up ($p < 0.001$). The mean VAS score decreased from $8.7 \pm 2.2$ (range, 0–10) preoperatively to $5.2 \pm 2.5$ (range, 0–6) at the latest follow-up ($p < 0.001$) (Table 2).

Relative to the capacity for stair climbing, 17 (73.9%) patients were included in group C (up and down with rail) and 6 (26.1%) in group D (up with rail, unable down) in the preoperative period, while 14 (60.9%) patients were included in group A (normal up and down), 7 (30.4%) patients in group B (normal up, down with rail), and 2

![Fig. 3](image-url) The harvested fat is transferred into the Lipogems ortho kit (a, b) to microfragment the adipose tissue (and activate the ASCs) and to wash it through a saline solution.
(8.7%) in group C (up and down with rail) at the latest follow-up (Table 3).

No significant differences in improvements of IKS knee and function and VAS scores were found between patients of different ages (< 60 versus ≥ 60 years). Similarly, no significant differences in improvements of IKS and VAS scores were found between the other subgroups of patients: < 30 versus ≥ 30 kg/m² BMI, and stage 1–2 (early) versus stage 3 (moderate) PFOA (Table 4).

Of the 23 patients, 21 (91.3%) expressed total or near-total satisfaction with the final outcome and improvements with respect to knee function, pain, and capacity for climbing stairs. In particular, 17 (73.9%) patients reported complete or near-complete function recovery and/or pain relief, considering the procedure as excellent, and 4 (17.3%) patients achieved a satisfying function recovery and/or pain reduction, considering the procedure as good. Two (8.6%) patients of the preoperative group D (up with rail, unable down) reported a sufficient reduction of pain but were not able to recover a complete capacity to stair climbing (group C, up and down with rail) at the latest follow-up, considering the procedure as fair.

Adverse events were only related to the fat-harvesting procedure. Two patients developed a transitory hematoma of the abdominal region that did not influence the postoperative knee recovery. Neither infections nor neurovascular complications developed. A relative reduction of analgesic consumption in the postoperative period was noted, although not statistically investigated.

**Discussion**

The most important finding of this study was that intraarticular injection of autologous microfragmented adipose tissue rich in ASCs following arthroscopic debridement (chondral shaving/abrasion and/or meniscal regularization) significantly and considerably increased the IKS knee and function scores and significantly decreased the VAS scores in patients with isolated primitive PFOA at a mean follow-up of almost 2 years (range, 15–30 months).
The improvements in the IKS and VAS scores were not significantly affected by age, BMI, or stage of PFOA (grade 1–3). At the latest follow-up, 21 (91.3%) patients expressed satisfaction with the final outcome and improvements with regards to knee function, pain, and capacity to climb stairs, considering the procedure received as excellent (73.9% of the patients) or good (17.3% of the patients). Only two (8.6%) patients considered the procedure as fair; those patients of preoperative group D (up with rail, unable down) reported an acceptable reduction of pain and only partially improved their ability to climb stairs (group C, up and down with rail, at the latest follow-up). There were no treatment-related adverse events regarding the knee procedure. The lack of adverse events regarding the potential postoperative effusion even after injection of a high quantity of adipose tissue (10–15 ml) could be explained by the new technique of fat lavage and microfragmentation of the Lipogems.

### Table 1 Demographic data

| Total number | 23 patients |
|--------------|-------------|
| Age (years), mean ± SD (range) | 58 ± 8 (45–78) |
| Gender | |
| Male | 8 patients |
| Female | 15 patients |
| PFOA stage (Iwano) | |
| Stage 1 | 5 knees |
| Stage 2 | 11 knees |
| Stage 3 | 7 knees |
| Side | |
| Right | 14 knees |
| Left | 9 knees |
| BMI (kg/m²), mean ± SD (range) | 28.0 ± 4.8 (21–37) |
| Follow-up (months), mean ± SD (range) | 22.1 ± 4.2 (15–30) |

**SD** standard deviation, **PFOA** patellofemoral osteoarthrosis, **BMI** body mass index

### Table 2 Mean ± SD (range) of IKS knee and function and VAS scores

| Value | Preoperatively | Latest follow-up | p-Value |
|-------|----------------|------------------|---------|
| Mean IKS knee (points) | 35.6 ± 14.9 (14–79) | 61.9 ± 17.8 (27–92) | < 0.001 |
| Mean IKS function (points) | 52.0 ± 14.7 (25–70) | 82.3 ± 19.1 (35–100) | < 0.001 |
| VAS (points) | 8.7 ± 2.2 (0–10) | 5.2 ± 2.5 (0–6) | < 0.001 |

**SD** standard deviation, **IKS** international knee scores, **VAS** visual analog scale

Paired t-test (p < 0.05)
Table 3 Capacity for climbing stairs

| Group: description                  | Preoperatively   | Latest follow-up | p-Value |
|------------------------------------|------------------|------------------|---------|
| A: normal up and down               |                  |                  |         |
| B: normal up, down with rail       |                  |                  |         |
| C: up and down with rail           |                  |                  |         |
| D: up with rail, unable down       |                  |                  |         |
| E: unable                          |                  |                  |         |

| Pearson’s chi-square test (p < 0.05) |

Table 4 Differences in improvements of IKS knee and function and VAS scores relative to the age and BMI of patients and stage of PFOA

| Variable (no patients) | VAS | IKS knee | IKS function |
|------------------------|-----|----------|--------------|
| Age ≥ 60 (9)           | 3.7 ± 2.1 | 24.3 ± 19.8 | 28.3 ± 14.1  |
| Age < 60 (14)          | 3.4 ± 2.5 | 27.5 ± 20.4 | 31.7 ± 18.1  |
| p-Value                | 0.50 | 0.80     | 0.46         |
| BMI ≥ 30 (8)           | 3.1 ± 1.7 | 27.1 ± 18.8 | 30.3 ± 13.8  |
| BMI < 30 (15)          | 3.8 ± 2.6 | 25.8 ± 20.9 | 30.6 ± 18.1  |
| p-Value                | 0.14 | 0.55     | 0.70         |
| Iwano stage 1–2 (16)   | 3.9 ± 2.6 | 29.1 ± 20.1 | 32.8 ± 14.9  |
| Iwano stage 3 (7)      | 2.7 ± 1.4 | 19.7 ± 18.7 | 25 ± 19.5    |
| p-Value                | 0.16 | 0.73     | 0.15         |

IKS international knee scores, VAS visual analog scale, SD standard deviation, BMI body mass index

Unpaired t-test (p < 0.05)

degeneration. In this context, the stage of PFOA was not a tool in predicting the patient outcome, as the postoperative improvements of IKS and VAS scores were not significantly correlated to the severity of PFOA; in stage 3 patients, the microfragmented fat transfer following arthroscopic debridement could also provide clinical and functional benefits. Existing literature lacks evidence on the results in patients with isolated primary PFOA treated with autologous microfragmented adipose tissue injection, focusing on results obtained in patients with generic knee OA [17, 28]. To our knowledge, only three studies have been previously published on alternative joint-preservation treatments of isolated primary PFOA: the first of these reported the results of concomitant intraarticular injection of MSCs and PRP [32], the second evaluated the efficacy and safety of autologous protein solution injection [36], the third evaluated treatment with autologous bone marrow mononuclear cells injection associated with arthroscopic debridement [14]. However, Pintat et al. [32] and Van Genechten et al. [36] showed how PFOA symptoms were recalcitrant to those treatments after 1 year of follow-up, while the present study reported good improvement at a mean follow-up of almost 2 years. On the other hand, Guimaraes et al. [14] reported the results at 2 years of follow-up, but only eight patients were treated and with different doses (range, 30–87 ml) of bone marrow mononuclear cells, while in the present study 23 patients received a standard (and recognized) dose of 10–15 ml of microfragmented adipose tissue.

As already mentioned, IKS and VAS scores were not significantly affected by age, BMI of patients, or stage of PFOA. In particular, improvements in the IKS and VAS scores were not significantly different in the various groups of patients in relation to age (< 60 versus > 60 years), BMI (< 30 versus ≥ 30 kg/m²), or PFOA stage (early stage 1 or 2 versus moderate stage 3). These findings suggest how the injection of microfragmented autologous adipose tissue, due to its extraordinary lubricating capacity, could be indicated both for younger patients (< 60 years) who generally present a higher functional demand, and for overweight or obese patients (in
which a higher dose, 15 ml, of microfragmented adipose tissue is generally preferred). Additionally, this procedure could be beneficial in older patients (> 60 years), probably due to the fact that the concentration and the chondrogenic potential of ASCs are not strictly related to the age of the patient [5, 7]. On the other hand, the results of this study could confirm how this procedure could produce effective results in normal and underweight patients (in which the amount of lipoaspiration is often inferior resulting in not more than 10 ml of injected microfragmented adipose tissue) and in older patients, since the beneficial effect of the adipose-tissue injection is not strictly correlated to the number and concentration of the ASCs [6, 31].

It is interesting to note how, in this study, most patients significantly recovered and/or improved their ability to climb stairs: in the preoperative period, 17 patients were included in group C (up and down with rail) and 6 in group D (up with rail, unable down), while at the latest follow-up almost all (91.3%) patients were included in group A (normal up and down) or B (normal up, down with rail). On the other hand, the decrease in the VAS scores, although significant, was not conspicuous (from 8.7 points preoperatively to 5.2 points at the latest follow-up). This could be partly explained with the primary mechanical effect of the fat transfer (in terms of high articular lubrication) with consequent immediate restoration of the knee motion and function and, therefore, stair-climbing ability. On the other hand, the initial absence of the secondary biological effect of the ASCs inoculation (in terms of potential cartilage regeneration) associated to the persistence of knee synovitis due to the preexisting OA and to a possible inflammatory response to the adipose-tissue injection [1, 31] could explain the lack of conspicuous pain reduction. The surgeon could and should take into account this possibility and inform the patient preoperatively.

In our department, knee arthroscopy is always associated with the adipose-tissue injection to treat any intraarticular lesions and favor the possible future cartilage regeneration potentially induced by the ASCs [34]. In a recent meta-analysis including 18 clinical trials on the efficacy of MSCs (including ASCs, bone marrow-derived MSCs, synovial-derived MSCs, and peripheral blood-derived MSCs) in treating patients with generic knee OA, Cui et al. [22] extrapolated that patients with arthroscopic debridement and/or lower degrees of OA achieved higher outcomes. In this regard, it is important to stress again that none of the patients in this study presented a severe stage 4 PFOA. In this regard, in our department, the procedure of arthroscopy plus percutaneous fat transfer was not preferred in patients with a bone-on-bone tibiofemoral or patellofemoral OA, with the exception of patients with severe contraindications to major surgery.

The main limitation of this study was that a nonrandomized case-series was presented. Twenty-three patients with early or moderate isolated primary PFOA treated with the intraarticular injection of adipose tissue with ASCs following arthroscopic debridement were retrospectively analyzed, but results were not compared with any control group of patients treated only through an arthroscopic debridement. However, it is universally recognized that arthroscopic debridement alone (especially when performed exclusively for chondral shaving/abrasion and/or meniscal regularization without any meniscectomy or cartilage repair) is rather ineffective in improving symptoms of knee joint degeneration [13, 23]; therefore, the assumption was taken that the arthroscopic procedure in PFOA could not confound the real effectiveness of the knee injection of adipose tissue with ASCs. Similarly, one could object that in some patients, arthroscopic meniscal regularization could have improved symptoms instead of the fat transfer. All the patients that underwent meniscal regularization presented only degenerative meniscal tears in which the clinical effectiveness of the arthroscopic treatment is still highly controversial [2]. In our department, patients with recent trauma of the symptomatic knee and evident acute involvement of menisci (and/or ligaments) were originally excluded to receive this treatment protocol. Another limitation was no control group of patients treated only with adipose tissue injection without arthroscopy was included. As previously mentioned, the results of the fat transfer used as unique procedure in knee OA has already been reported to provide conflicting results in many other studies [1, 6, 22, 31]; moreover, in those studies, arthroscopic debridement has often been believed to interfere positively both with the lubricating effect of the adipose tissue and its potential capacity of stimulating the cartilage regeneration. Another limitation of this study could be that the mean follow-up (22.1 months) was quite short; however, the authors did not identify any deterioration of clinical and functional results over time, even in patients with longer follow-ups (30 months). Finally, another important limitation was that potential biological effect of the ASCs was not evaluated, neither through MRI or an arthroscopic second-look. In that regard, no patient asked for additional surgical treatment, and the authors preferred following the patients clinically and functionally, therefore carrying out only a clinical study. Similarly, the adipose tissue injected into the knee was not previously analyzed, especially concerning the number or concentration of ASCs. Anyway, it has already been widely reported how the clinical and functional results of the intraarticular injection of adipose tissue are
not strictly and significantly correlated to the dose and number of ASCs they contain [21, 31]. Despite these limitations, the clinical relevance of this study is that the injection of autologous adipose tissue with ASCs associated with arthroscopic debridement is a safe and effective procedure for significantly increasing the clinical and functional scores in patients with early-to-moderate isolated primary PFOA, at a mean follow-up of almost 2 years. These results appear much more relevant when considering how the management of the first stages of the primary PFOA could be rather challenging, since conservative treatment results are often ineffective, while major surgeries or joint replacement are absolutely premature. While this study was not designed to demonstrate the biological effectiveness of the ASCs contained in the adipose tissue, nor the superiority of the adipose tissue knee injection compared with other therapies, these results failed to identify a category of patients (relative to age, BMI, or PFOA stage) who were more likely to take advantage of this protocol. Obviously, large prospective randomized clinical trials and longer follow-ups are necessary, also to evaluate the potential cartilage regeneration secondary to the advocated biologic effect derived by the inoculation of ASCs. Given the relatively high cost of this procedure, a secondary biologic effect in terms of cartilage regeneration would be strongly expected to potentially secure longer patient benefits, beyond clinical scores improvements that could be transitory.

Conclusion

Intraarticular injection of autologous microfragmented adipose tissue rich in ASCs following knee arthroscopy for chondral shaving/abrasion and/or meniscal regularization significantly improved overall clinical and functional scores in patients with early or moderate isolated primary PFOA at a mean follow-up of almost 2 years. IKS and VAS scores were not significantly affected by age, BMI, or stage of PFOA. There were no treatment-related adverse events with regards to the knee procedure. The hope remains that the biological effect of this protocol could positively interfere with the natural history of PFOA.

Authors’ contributions

M.V. contributed to the conception and design of the study, the interpretation of data and the drafting of the manuscript. G.T. and L.C. contributed to data collection. K.C. performed the initial data collection and statistical analysis and contributed to the interpretation and drafting of the manuscript. A.S.P. performed the final review of the manuscript. All authors read and approved the final manuscript.

Funding

No funding was received for this work.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

This study was exempt from institutional approval.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Multidisciplinary Department of Medico-Surgical and Dentistry Specialties, “Luigi Vanvitelli” University of Campania, Naples, Italy. 2 Department of Medicine and Health Sciences “Vincenzo Tiberio”, University of Molise, Campobasso, Italy.

Received: 19 July 2021 Accepted: 25 January 2022 Published online: 05 February 2022

References

1. Adriani E, Moio M, Di Paola B, Salustri W, Alferi A, Parisi P, Ruggiero M, Bonab Z, Carlesimo B (2017) Percutaneous fat transfer to treat knee osteoarthritis: preliminary results. Joints 5:89–92
2. Beaufils P, Becker R, Kopf S, Englund M, Verdonk R, Ollivier M, Seil R (2017) Surgical management of degenerative meniscus lesions: the 2016 ESSKA meniscus consensus. Knee Surg Sports Traumatol Arthrosc 25:335–346
3. Bianchi F, Maioli M, Leonardi E, Olivi E, Pasquini G, Valente S, Mendez AJ, Ricordi C, Raffaiari M, Tremolada C, Ventura C (2013) A new nonenzymatic method and device to obtain a fat tissue derivative highly enriched in pericyte-like elements by mild mechanical forces from human lipoaspirates. Cell Transplant 22:2063–2077
4. Caplan AI (2015) Adult mesenchymal stem cells: when, where, and how. Stem Cells Int 2015:628767. https://doi.org/10.1155/2015/628767
5. Coughlin RP, Oldewiller A, Mickelson DT, Moorman CT (2017) Adipose-derived stem cell transplant technique for degenerative joint disease. Arthrosc Tech 6:e1761–e1766
6. Cui GH, Wang YY, Li CI, Shi CH, Wang WS (2016) Efficacy of mesenchymal stem cells in treating patients with osteoarthritis of the knee: a meta-analysis. Exp Ther Med 12:3390–3400
7. Damaia E, Chicharro D, Lopez S, Cuervo B, Rubio M, Sopena JJ, Vilar JM, Carrillo JM (2018) Adipose-derived mesenchymal stem cells: are they a good therapeutic strategy for osteoarthitits? Int J Mol Sci 19(7):1926
8. De Deugd CM, Pareeek A, Krych AJ, Cummings NW, Dahm DL (2017) Outcomes of patellofemoral arthroplasty based on radiographic severity. J Arthroplasty 32(4):1137–1142
9. Dejour D, Saffann M, Malemo Y, Pungitore M, Valluy J, Nover L, Derme G (2019) Early outcomes of an anatomic trochlear-cutting patellofemoral arthroplasty: patient selection is key. Knee Surg Sports Traumatol Arthrosc 27(7):2297–2302
10. Delanois RE, McGrath MS, Ulrich SD, Marker DR, Seyler TM, Bonutti PM, Mont MA (2008) Results of total knee replacement for isolated patellofemoral arthritis: when not to perform a patellofemoral arthroplasty. Orthop Clin North Am 39(3):381–388
11. Freitag J, Bates D, Wickham J, Shah K, Huguenin L, Tenen A, Paterson K, Boyd R (2019) Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial. Regen Med 14:213–230
12. Garza JR, Campbell RE, Tjoumakaris FP, Freedman KB, Miller LS, Santa Maria D, Tucker BS (2020) Clinical efficacy of intra-articular mesenchymal stromal cells for the treatment of the knee osteoarthritis. a double-blinded prospective randomized controlled clinical trial. Am J Sports Med 48(3):588–598
13. Grieshofer JA, Stanton M, Gambardella R (2016) Debridement of articular cartilage: the natural course. Sports Med Arthrosc Rev 24:56–62
14. Guimãres MV, da Graça Morais Rios PA, Ruiz MA, Noronha CP, Terra DL, Lana JFD (2018) Patellofemoral osteoarthritis: treatment with autologous bone marrow mononuclear cells and arthroscopic surgery, a prospective study. Stem Cell Regener Med 2:2–7

15. Hong Z, Chen J, Zhang S, Zhao C, Bi M, Chen X, Bi Q (2019) Intra-articular injection of autologous adipose-derived stromal vascular fractions for knee osteoarthritis: a double-blind randomized self-controlled trial. Int Orthop 43:1123–1134

16. Hudetz D, Bonc I, Rod E, Jelec Z, Racić A, Vrdoljak T, Skelin A, Lauc G, Trbojević-Akmarđić I, Plčeko M, Polšek O, Primorac D (2017) The effect of intra-articular injection of autologous microfragmented fat tissue on proteoglycan synthesis in patients with knee osteoarthritis. Genes 8(10):270

17. Hurley ET, Yasui Y, Gianakos AL, Seow D, Shimozono Y, Kerkhoffs GMMJ, Kennedy JG (2018) Limited evidence for adipose-derived stem cell therapy on the treatment of osteoarthritis. Knee Surg Sports Traumatol Arthrosoc. 26:3499–3507

18. Insall JN, Dorr LD, Scott RD, Scott WN (1989) Rationale of the Knee Society clinical rating system. Clin Orthop Relat Res. 248:13–14

19. Iwano T, Kurosawa H, Tokuyama H, Hoshikawa Y (1990) Roentgenographic and clinical findings of patellofemoral osteoarthritis. With special reference to its relationship to femorotibial osteoarthrosis and etiologic factors. Clin Orthop Relat Res 252:190–197

20. Jin YZ, Lee JH (2018) Mesenchymal stem cell therapy for bone regeneration. Clin Orthop Relat Res 10:271–278

21. Jo CH, Choi JW, Jeong EC, Oh S, Shin JS, Shim H, Yoon KS (2017) Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a 2-year follow-up study. Am J Sports Med 45:2774–2783

22. Jo CH, Lee YG, Shin WH (2014) Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof of concept clinical trial. Stem Cells 32:1254–1266

23. Katz JN, Brownlee SA, Jones MH (2014) The role of arthroscopy in the management of knee osteoarthritis. Best Pract Res Clin Rheumatol 28:143–156

24. Kobayashi S, Pappas E, Fransen M, Refshauge K, Simic M (2016) The prevalence of patellofemoral osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartil 24(10):1697–1707

25. Lankhorst NE, Damen J, Oei EH, Verhaar JAN, Kloppenburg M, Bierma-Zeinstra SMA, van Middelkoop M (2017) Incidence, prevalence, natural course and prognosis of patellofemoral osteoarthritis: the Cohort Hip and Cohort Knee study. Osteoarthr Cartil 25(S1):647–653

26. Lee WS, Kim HJ, Kim KI, Kim GB, Jin W (2019) Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase IIb randomized, placebo-controlled clinical trial. Stem Cells Transl Med 8(6):504–511

27. Lu L, Dai C, Zhang Z, Du H, Li S, Ye P, Fu Q, Zhang L, Wu X, Dong Y, Song Y, Zhao D, Pang Y, Bao C (2019) Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase I ib clinical trial. Stem Cell Res Ther 10(1):143

28. Ma W, Liu C, Wang S, Xu H, Sun H, Fan X (2019) Efficacy and safety of intra-articular injection of mesenchymal stem cells in the treatment of knee osteoarthritis. A systematic review and meta-analysis. Medicine 99(49):e23343

29. Merceran E, Potron S, Masson M, Fellah BH, Gauthier Q, Lesoeur J, Chérel Y, Weiss P, Guicheux J, Vinatier C (2010) Cartilage tissue engineering from hydrogel to mesenchymal stem cells. Biomed Mater Eng 20:159–166

30. Misso ML, Pitt VJ, Jones KM, Barnes HN, Piterman L, Green SE (2008) Quality and consistency of clinical practice guidelines for diagnosis and management of osteoarthritis of the hip and knee: a descriptive overview of published guidelines. Med J Aust 189:394–399

31. Pers YM, Rackwitz L, Ferreira R, Pullig Q, Delfour C, Barry F, Sensebe L, Castella L, Fleury S, Bourin P, Noël D, Canovas F, Cyteval C, Lisignoli G, Schratt J, Haddad D, Domergue S, Noeth U, Jorgensen C, ADiPOA Consortium (2016) Adipose mesenchymal stromal cell-based therapy for severe osteoarthritits of the knee: a phase I dose-escalation trial. Stem Cells Transl Med 5:847–856

32. Pintat J, Silvestre A, Magalon G, Gadeau AP, Pesquer L, Perazziello A, Peuchant A, Mouyayer C, Dallaudière B (2017) Intra-articular injection of mesenchymal stem cells and platelet-rich plasma to treat patellofemoral osteoarthritis: preliminary results of a long-term pilot study. J Vasc Inter Radiol 28(12):1708–1713

33. Rodriguez-Merchan EC (2020) The present situation of patellofemoral arthroplasty in the management of solitary patellofemoral osteoarthritis. Arch Bone Jt Surg 8(3):325–331

34. Schiavone Panni A, Del Regno C, Mazzitelli G, D’Apollo R, Corona K, Vasso M (2017) Good clinical results with autologous matrix-induced chondrogenesis (Amic) technique in large knee chondral defects. Knee Surg Sports Traumatol Arthrosoc. 26(4):1130–1136

35. Schiavone Panni A, Vasso M, Braile A, Toro G, De Cicco A, Viggiano D, Lepore F (2019) Preliminary results of autologous adipose-derived stem cells in early knee osteoarthritis: identification of a subpopulation with greater response. Int Orthop 43:7–13

36. Van Genechten W, Vuylsteke K, Swinnen L, Martinez PR, Verdonk P (2020) Autologous protein solution as selective treatment for advanced patellofemoral osteoarthritis in the middle-aged female patients: 54% response rate at 1-year follow-up Knee Surg Sports Traumatol Arthrosoc. https://doi.org/10.1007/s00167-020-06064-8

37. van Jonbergen HP, Werkman DM, Barnaart LF, van Kampen A (2010) Long-term outcomes of patellofemoral arthroplasty. J Arthroplasty 25:1066–1071

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com